UA73748C2 - Medicaments for the treatment of cancer - Google Patents

Medicaments for the treatment of cancer Download PDF

Info

Publication number
UA73748C2
UA73748C2 UA2002032524A UA2002032524A UA73748C2 UA 73748 C2 UA73748 C2 UA 73748C2 UA 2002032524 A UA2002032524 A UA 2002032524A UA 2002032524 A UA2002032524 A UA 2002032524A UA 73748 C2 UA73748 C2 UA 73748C2
Authority
UA
Ukraine
Prior art keywords
methyl
phenyl
dihydro
oxoquinoline
carboxamide
Prior art date
Application number
UA2002032524A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of UA73748C2 publication Critical patent/UA73748C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UA2002032524A 1999-10-25 2000-10-24 Medicaments for the treatment of cancer UA73748C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (1)

Publication Number Publication Date
UA73748C2 true UA73748C2 (en) 2005-09-15

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002032524A UA73748C2 (en) 1999-10-25 2000-10-24 Medicaments for the treatment of cancer

Country Status (21)

Country Link
EP (1) EP1224172B1 (zh)
JP (1) JP3950337B2 (zh)
KR (2) KR100674160B1 (zh)
AT (1) ATE358668T1 (zh)
AU (1) AU775057B2 (zh)
CA (1) CA2386775C (zh)
CZ (1) CZ298534B6 (zh)
DE (1) DE60034240T2 (zh)
DK (1) DK1224172T3 (zh)
EE (1) EE200200207A (zh)
ES (1) ES2280258T3 (zh)
HK (1) HK1049830A1 (zh)
HR (1) HRP20020353A2 (zh)
HU (1) HU229072B1 (zh)
IL (2) IL148782A0 (zh)
IS (1) IS2750B (zh)
NO (1) NO323320B1 (zh)
NZ (1) NZ518296A (zh)
SE (1) SE0002320D0 (zh)
UA (1) UA73748C2 (zh)
WO (1) WO2001030758A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
WO2007047863A2 (en) 2005-10-19 2007-04-26 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
KR101495327B1 (ko) 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
CA2736091A1 (en) 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
RU2013120556A (ru) * 2010-10-14 2014-11-20 Иммунар Аб 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
MX2015005632A (es) * 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
BR112015021602A2 (pt) 2013-03-14 2017-07-18 Teva Pharma cristais de laquinimod de sódio e processo melhorado para a fabricação dos mesmos
KR102533033B1 (ko) * 2014-09-23 2023-05-15 액티브 바이오테크 에이비 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
AU2015348778B2 (en) 2014-11-19 2020-12-24 Active Biotech Ab Quinoline carboxamides for use in the treatment of leukemia
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Axl阻害剤を有効成分として含む固形がん治療剤
JP2023519153A (ja) 2020-03-03 2023-05-10 アクティブ バイオテック エイビー 組合せ療法における使用のためのタスキニモドまたはその薬学的に許容される塩
AU2021275994A1 (en) * 2020-05-21 2022-12-22 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
JP2024520307A (ja) 2021-05-25 2024-05-24 アクティブ バイオテック エイビー 複数のタスキニモド粒子およびその使用
EP4363404A1 (en) 2021-07-02 2024-05-08 Active Biotech AB A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) * 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
EP1224172A1 (en) 2002-07-24
NZ518296A (en) 2003-06-30
HRP20020353A2 (en) 2005-10-31
KR100674160B1 (ko) 2007-01-24
EE200200207A (et) 2003-06-16
WO2001030758A1 (en) 2001-05-03
CA2386775C (en) 2004-07-13
CZ20021293A3 (cs) 2002-07-17
DK1224172T3 (da) 2007-08-13
HUP0203238A3 (en) 2003-05-28
IL148782A0 (en) 2002-09-12
DE60034240T2 (de) 2007-12-20
KR100597938B1 (ko) 2006-07-06
CA2386775A1 (en) 2001-05-03
EP1224172B1 (en) 2007-04-04
AU775057B2 (en) 2004-07-15
JP2003512454A (ja) 2003-04-02
AU1185101A (en) 2001-05-08
KR20020043646A (ko) 2002-06-10
HK1049830A1 (zh) 2003-05-30
KR20060054496A (ko) 2006-05-22
DE60034240D1 (de) 2007-05-16
HUP0203238A2 (hu) 2003-01-28
CZ298534B6 (cs) 2007-10-31
SE0002320D0 (sv) 2000-06-21
IS6329A (is) 2002-04-02
IL148782A (en) 2007-05-15
HU229072B1 (en) 2013-07-29
NO323320B1 (no) 2007-03-12
JP3950337B2 (ja) 2007-08-01
NO20021932D0 (no) 2002-04-24
IS2750B (is) 2011-08-15
ES2280258T3 (es) 2007-09-16
ATE358668T1 (de) 2007-04-15
NO20021932L (no) 2002-06-21

Similar Documents

Publication Publication Date Title
UA73748C2 (en) Medicaments for the treatment of cancer
US6395750B1 (en) Drugs for the treatment of malignant tumors
AU2006301708B2 (en) Glycyrrhetinic acid-30-amide derivatives and the uses thereof
KR20190026827A (ko) 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
AU553775B2 (en) (1-(2-benzoxazolyl)hydrazino)alkyl nitrile derivatives
KR20150038363A (ko) 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르
CA2150162C (fr) Nouveau n-pyridyl carboxamides et derives, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
CZ20003849A3 (cs) Deriváty chinolinu
WO2018157842A1 (zh) 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
JPS5989625A (ja) 芳香族置換環状アミジン止瀉剤
EP3006432B1 (en) 2,3-butanediamide epoxide compound and preparation method and use thereof
HU195486B (en) Process for preparing new pyridine derivatives
RU2300532C2 (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
RU2240313C2 (ru) Лекарственные средства для лечения злокачественных опухолей
US20040267015A1 (en) Peptide deformylase inhibitors
CN102260187B (zh) 取代的氨甲酰基环己甲酸类化合物及其制法和用途
WO2016019588A1 (en) Oxacazone compounds to treat clostridium difficile
CH629194A5 (fr) Amino aryl triazines-1,2,4 utilisables dans le traitement d'algies diverses.
US10385040B2 (en) Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
US2762806A (en) 2, 3-alkylenedioxy-6-nitro-9-aminoacridines and their synthesis
JPS6312870B2 (zh)
CN113735788A (zh) 布洛芬三唑硫醇衍生物及其在制备新冠病毒抑制剂中应用
JPH0157114B2 (zh)
EP0022737A1 (fr) Imines dérivées de l'amino-5 benzodioxole-1,3 utiles comme médicaments et leur préparation
JPS5984823A (ja) 抗炎症鎮痛剤組成物